| Chemotherapy-induced nausea and vomiting
Sancuso vs Akynzeo
Side-by-side clinical, coverage, and cost comparison for chemotherapy-induced nausea and vomiting.Deep comparison between: Sancuso vs Akynzeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAkynzeo has a higher rate of injection site reactions vs Sancuso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Akynzeo but not Sancuso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sancuso
Akynzeo
At A Glance
Transdermal
Single patch, up to 7 days
5-HT3 receptor antagonist
Oral or IV infusion
Once per chemotherapy cycle
NK-1 / 5-HT3 receptor antagonist
Indications
- Chemotherapy-induced nausea and vomiting
- Chemotherapy-induced nausea and vomiting
Dosing
Chemotherapy-induced nausea and vomiting Apply a single transdermal system to the upper outer arm 24-48 hours before chemotherapy; wear for at minimum 24 hours after chemotherapy is completed, up to 7 days total; each system releases 3.1 mg granisetron per 24 hours.
Chemotherapy-induced nausea and vomiting 1 capsule orally 1 hour before, or 1 vial IV over 30 minutes starting 30 minutes before, each chemotherapy cycle; administer with dexamethasone.
Contraindications
- Known hypersensitivity to granisetron or any component of the transdermal system
—
Adverse Reactions
Most common (>=3%) Constipation, headache
Serious Progressive ileus and gastric distention, serotonin syndrome, skin reactions, increased drug exposure with external heat sources, phototoxicity with ultraviolet light exposure
Postmarketing Application site reactions (pain, pruritus, erythema, rash, irritation, vesicles, burn, discoloration, urticaria), transdermal system non-adhesion, bradycardia, chest pain, palpitations, sick sinus syndrome
Most common (>=3%) Headache, asthenia, fatigue, dyspepsia, constipation, erythema
Serious Hypersensitivity reactions, serotonin syndrome
Pharmacology
Granisetron is a selective 5-HT3 receptor antagonist that blocks serotonin-3 receptors located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone, preventing chemotherapy-induced serotonin release from stimulating the vomiting reflex.
Netupitant is a selective NK-1 receptor antagonist that blocks substance P-mediated delayed emesis; palonosetron is a 5-HT3 receptor antagonist that inhibits serotonin-mediated acute emesis at vagal afferents and the chemoreceptor trigger zone.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sancuso
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (1/12) · Qty limit (9/12)
Akynzeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Sancuso
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Akynzeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Sancuso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Akynzeo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Sancuso.
No savings programs available for Akynzeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SancusoView full Sancuso profile
AkynzeoView full Akynzeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.